Yang Hung-Hsu, Hsiao Yu-Ping, Shih Hung-Chun, Yang Jen-Hung
Department of Dermatology, Chung Shan Medical University Hospital, Taichung, Taiwan 402.
Int J Dermatol. 2007 Aug;46(8):883-4. doi: 10.1111/j.1365-4632.2007.03269.x.
A 70-year-old man developed herpes zoster over the right L5-S2 region for 3 days and was admitted for acyclovir therapy. He had a medical history of rectal cancer status post-colostomy and end-stage renal disease undergoing thrice weekly hemodialysis. Without a prior loading dose, acyclovir 500 mg (7.7 mg/kg) daily was given intravenously in two divided doses. On the third dosage, the patient became confused and agitated and developed insomnia. Within the following 24 h, delirium, visual and auditory hallucinations, disorientation to place and time, as well as impaired recent memory occurred. At the same time, a transient low grade fever (38 degrees C) was noted but resolved spontaneously after ice pillow (Fig. 1). The etiology was vigorously explored. He had no history of any neurological or psychiatric disorders. Drug history was reviewed, but no other medications besides acyclovir were currently being used. Physical examination revealed neither meningeal signs nor focal neurological deficits. Serum blood urea nitrogen, glucose, and electrolytes were within normal limits except for an elevated creatinine level at 6.2 and 5.7 mg/dl (before and after neuropsychotic symptoms, respectively). Complete blood count with differentiation was also unremarkable. Cerebrospinal fluid examination was not possible as the patient's family refused the lumbar puncture. Moreover, an electroencephalograph study and head computed tomography scan disclosed no abnormalities. Acyclovir-induced neurotoxicity was suspected. Therefore, acyclovir was discontinued. Subsequently, serum acyclovir and CMMG were checked by enzyme-linked immunosorbent assay. Serum acyclovir level was 1.6 mg/l (normal therapeutic level, 0.12-10.8 mg/l) and CMMG level was 5 mg/l. Emergent hemodialysis (4-h/session) was given; the neuropsychotic symptoms, including agitation, delirium, and visual and auditory hallucinations, greatly abated after the second session. The patient fully recovered after three consecutive days of hemodialysis; the serum was rechecked and revealed that the acyclovir level was below 0.5 mg/l and the CMMG level was undetectable. At the same time, his herpetic skin lesions resolved well.
一名70岁男性右侧L5 - S2区域出现带状疱疹3天,因阿昔洛韦治疗入院。他有直肠癌结肠造口术后病史以及终末期肾病,每周接受三次血液透析。未给予负荷剂量,每日静脉注射阿昔洛韦500mg(7.7mg/kg),分两次给药。在第三次给药时,患者出现意识模糊、烦躁不安并失眠。在接下来的24小时内,出现谵妄、视幻觉和听幻觉、地点和时间定向障碍以及近期记忆力受损。同时,出现短暂低热(38摄氏度),但使用冰枕后自行消退(图1)。对病因进行了深入探究。他没有任何神经或精神疾病史。复查用药史,除阿昔洛韦外目前未使用其他药物。体格检查未发现脑膜刺激征和局灶性神经功能缺损。血清血尿素氮、血糖和电解质均在正常范围内,只是肌酐水平升高,分别为6.2mg/dl和5.7mg/dl(分别在出现神经精神症状之前和之后)。全血细胞计数及分类也无异常。由于患者家属拒绝腰椎穿刺,无法进行脑脊液检查。此外,脑电图检查和头部计算机断层扫描未发现异常。怀疑为阿昔洛韦诱导的神经毒性。因此,停用阿昔洛韦。随后,通过酶联免疫吸附测定法检测血清阿昔洛韦和CMMG。血清阿昔洛韦水平为1.6mg/l(正常治疗水平为0.12 - 10.8mg/l),CMMG水平为5mg/l。进行紧急血液透析(每次4小时);第二次透析后,包括烦躁、谵妄以及视幻觉和听幻觉在内的神经精神症状明显减轻。连续三天血液透析后患者完全康复;复查血清显示阿昔洛韦水平低于0.5mg/l,CMMG水平无法检测到。同时,他的疱疹性皮肤病变愈合良好。